AR112357A1 - Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano - Google Patents
Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humanoInfo
- Publication number
- AR112357A1 AR112357A1 ARP180101480A AR112357A1 AR 112357 A1 AR112357 A1 AR 112357A1 AR P180101480 A ARP180101480 A AR P180101480A AR 112357 A1 AR112357 A1 AR 112357A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- extracellular domain
- kits
- procedures
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Composición para la unión a un anticuerpo anti-CD38, que comprende una forma recombinante soluble de un dominio extracelular de CD38 y/o un fragmento del mismo que interfiere con la actividad de unión de un anticuerpo anti-CD38, caracterizada por que la secuencia de la forma recombinante soluble del dominio extracelular de CD38 y/o el fragmento del mismo se selecciona del grupo que consiste en SEQ ID Nº 7, SEQ ID Nº 8, SEQ ID Nº 9, SEQ ID Nº 10, SEQ lD Nº 11, SEQ ID Nº 12, SEQ ID Nº 13, y SEQ ID Nº 14.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762543788P | 2017-08-10 | 2017-08-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR112357A1 true AR112357A1 (es) | 2019-10-23 |
Family
ID=62846219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101480 AR112357A1 (es) | 2017-08-10 | 2018-06-01 | Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11708418B2 (es) |
| EP (3) | EP4296680A3 (es) |
| JP (3) | JP6833851B2 (es) |
| KR (2) | KR102631281B1 (es) |
| CN (2) | CN117820498A (es) |
| AR (1) | AR112357A1 (es) |
| AU (2) | AU2018313028B2 (es) |
| BR (1) | BR112020002636A2 (es) |
| CA (1) | CA3070789A1 (es) |
| EA (1) | EA202090265A1 (es) |
| ES (1) | ES2911243T3 (es) |
| MX (1) | MX2020001489A (es) |
| PL (1) | PL3587445T3 (es) |
| PT (1) | PT3587445T (es) |
| TW (1) | TW201910349A (es) |
| UY (1) | UY37757A (es) |
| WO (1) | WO2019030581A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202000692A (zh) * | 2018-02-20 | 2020-01-01 | 美商格里佛診斷方法股份有限公司 | 包含GpIbα的多肽和組合物、編碼該多肽的核酸及包含該多肽或該核酸的細胞 |
| CN112048019B (zh) * | 2019-06-06 | 2023-05-09 | 鲁南制药集团股份有限公司 | 抗人cd47单克隆抗体 |
| WO2022056193A1 (en) * | 2020-09-10 | 2022-03-17 | Casi Pharmaceuticals, Inc. | Methods of blood screening |
| CN112285361B (zh) * | 2020-09-27 | 2023-12-05 | 中国人民解放军空军军医大学 | 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂 |
| CN114917413B (zh) * | 2022-06-14 | 2023-04-28 | 健诺维(成都)生物科技有限公司 | 一种负载重组多肽的羊膜及其制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| US6506551B1 (en) * | 1999-10-08 | 2003-01-14 | North Shore - Long Island Jewish Research Institute | CD38 as a prognostic indicator in B cell chronic lymphocytic leukemia |
| US20020102250A1 (en) * | 2000-06-30 | 2002-08-01 | Deibel Martin R. | Recombinant S. aureus peptide deformylase |
| MXPA06008700A (es) * | 2004-02-06 | 2007-01-19 | Morphosys Ag | Anticuerpos anti-cd38 humanos y usos para los mismos. |
| JP5476122B2 (ja) * | 2006-09-26 | 2014-04-23 | ゲンマブ エー／エス | Ｃｄ３８発現腫瘍の併用処置法 |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| CA2738566C (en) | 2008-10-01 | 2024-04-30 | Micromet Ag | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
| US20120034228A1 (en) * | 2008-10-01 | 2012-02-09 | Micromet Ag | CROSS-SPECIES-SPECIFIC PSCAxCD3, CD19xCD3, C-METxCD3, ENDOSIALINxCD3, EPCAMxCD3, IGF-1RxCD3 OR FAPALPHAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY |
| WO2010083253A2 (en) * | 2009-01-14 | 2010-07-22 | Viral Logic Systems Technology Corp. | Cd47 related compositions and methods for treating immunological diseases and disorders |
| ES2586579T3 (es) * | 2010-02-19 | 2016-10-17 | Xencor, Inc. | Nuevas inmunoadhesinas de CTLA4-IG |
| US20130029358A1 (en) * | 2010-04-01 | 2013-01-31 | Ludwig Institute For Cancer Research Ltd. | Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof |
| EP2530089A1 (en) * | 2011-06-03 | 2012-12-05 | Bayer Pharma Aktiengesellschaft | Neutralising prolactin receptor antibody Mat3 and its therapeutical use |
| US9599606B2 (en) * | 2014-06-10 | 2017-03-21 | The Board Of Regents Of The University Of Texas System | ADP-ribose detection reagents |
| MA40894A (fr) | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| US10806787B2 (en) * | 2015-02-16 | 2020-10-20 | Pharma Foods International Co., Ltd. | Anticancer agents or antimetastatic agents using FSTL1 and combination drug thereof |
| US9850288B2 (en) * | 2015-03-16 | 2017-12-26 | The Catholic University Of America | Method of purifying authentic trimeric HIV-1 envelope glycoproteins comprising a long linker and tag |
| HUE048111T2 (hu) * | 2015-03-23 | 2020-05-28 | Bayer Pharma AG | Anti-CEACAM6 ellenanyagok és alkalmazásuk |
| MA43219A (fr) * | 2015-11-10 | 2018-09-19 | Univ Medical Center Hamburg Eppendorf | Polypeptides de liaison d'antigène dirigés contre cd38 |
-
2018
- 2018-06-01 CN CN202410194213.6A patent/CN117820498A/zh active Pending
- 2018-06-01 CN CN201880000662.5A patent/CN109790210B/zh active Active
- 2018-06-01 EA EA202090265A patent/EA202090265A1/ru unknown
- 2018-06-01 KR KR1020187017279A patent/KR102631281B1/ko active IP Right Grant
- 2018-06-01 AR ARP180101480 patent/AR112357A1/es unknown
- 2018-06-01 PL PL19184018.0T patent/PL3587445T3/pl unknown
- 2018-06-01 EP EP23205907.1A patent/EP4296680A3/en active Pending
- 2018-06-01 BR BR112020002636-0A patent/BR112020002636A2/pt unknown
- 2018-06-01 EP EP18738376.5A patent/EP3464343B1/en active Active
- 2018-06-01 KR KR1020247002508A patent/KR20240015159A/ko active Application Filing
- 2018-06-01 UY UY0001037757A patent/UY37757A/es unknown
- 2018-06-01 ES ES18738376T patent/ES2911243T3/es active Active
- 2018-06-01 JP JP2018530834A patent/JP6833851B2/ja active Active
- 2018-06-01 CA CA3070789A patent/CA3070789A1/en active Pending
- 2018-06-01 EP EP19184018.0A patent/EP3587445B1/en active Active
- 2018-06-01 TW TW107119019A patent/TW201910349A/zh unknown
- 2018-06-01 AU AU2018313028A patent/AU2018313028B2/en active Active
- 2018-06-01 MX MX2020001489A patent/MX2020001489A/es unknown
- 2018-06-01 US US16/079,068 patent/US11708418B2/en active Active
- 2018-06-01 PT PT191840180T patent/PT3587445T/pt unknown
- 2018-06-01 WO PCT/IB2018/053939 patent/WO2019030581A1/en unknown
-
2021
- 2021-02-03 JP JP2021015874A patent/JP7289328B2/ja active Active
-
2023
- 2023-01-31 JP JP2023012758A patent/JP2023041802A/ja active Pending
- 2023-05-19 US US18/320,912 patent/US20240132616A1/en active Pending
- 2023-06-28 AU AU2023204121A patent/AU2023204121A1/en active Pending
- 2023-11-20 US US18/514,624 patent/US20240092929A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR112357A1 (es) | Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano | |
| CO2018000211A2 (es) | Moléculas de anticuerpo que se unen a cd45 | |
| TN2018000276A1 (en) | Inhibitors of receptor-interacting protein kinase 1. | |
| CO2018000104A2 (es) | Moléculas de anticuerpo que se unen a cd22 | |
| PH12019500540A1 (en) | Anti-pd-1 antibodies and their uses | |
| EA202190983A1 (ru) | Новое антитело к с-kit | |
| CO2018010458A2 (es) | Composiciones y anticuerpos anti-tim-3 | |
| CL2016003191A1 (es) | Polipéptidos receptores formulados y métodos relacionados | |
| MX2021001841A (es) | Anticuerpos anti-gdf15, composiciones y metodos de uso. | |
| DOP2016000225A (es) | Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda | |
| PH12018502456A1 (en) | Anti-cd04 antibodies and their uses | |
| PE20170140A1 (es) | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer | |
| MX2017011974A (es) | Estabilizacion del 1-cloro-3,3,3-trifluoropropeno. | |
| NZ730865A (en) | Peptides having anti-inflammatory properties | |
| BR112017006464A2 (pt) | bloqueio de cd73 | |
| PE20161175A1 (es) | Terapias de combinacion con anticuerpos anti-cd38 | |
| CL2018000107A1 (es) | Moléculas de anticuerpo que se unen a cd79 | |
| AU2016261707A8 (en) | Use of cannabis to treat fibromyalgia, methods and compositions thereof | |
| MX2022010755A (es) | Inhibidores de quinasa y usos de los mismos. | |
| MX2017008390A (es) | Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato. | |
| CY1124338T1 (el) | Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων | |
| DOP2021000130A (es) | Moduladores de la expresion de hsd17b13 | |
| MX2021005956A (es) | Composiciones biologicas secas y metodos de las mismas. | |
| MX2021008834A (es) | Metodos de tratamiento del cancer de mama con tucatinib. | |
| MX2020011027A (es) | Constructos de anticuerpos biespecíficos trivalentes. |